Recently, the CE01 Cell Sorter, independently developed by Suzhou Labris Biotech Co., Ltd., was officially installed at the Flow Cytometry Unit of the Yong Loo Lin School of Medicine, National University of Singapore (NUS). This collaboration will leverage the School's global leadership in precision medicine, translational medicine, immunology, and cancer research to drive the deep application of microfluidic cell sorting technology in the field of precision medicine.

A Leading Medical Research Institution in Asia

The Yong Loo Lin School of Medicine at NUS is the top-ranked medical school in Asia. Its Flow Cytometry Unit, a core research facility, provides critical technical support for cutting-edge fields such as precision medicine, cancer biology, immunotherapy, and stem cell research.

The facility serves numerous internationally renowned research groups, including those working on:

• Precision Cancer Therapy: e.g., rare cell research in gastric cancer, colorectal cancer, etc.

• Immune Regulation Mechanisms: application of T cell and B cell subset analysis in autoimmune diseases.

• Infection and Microbiomics: e.g., sepsis, gut microbiota-host immune interactions.

CE01 Cell Sorter: A New Generation of Cell Sorting Technology

The next-generation CE01 microfluidic cell sorter offers the following core advantages:

• High Capture Efficiency, High Viability, Broad Downstream Applications

• 90% capture of tumor cells from blood across multiple cancer types

• 95% cell viability, enabling various downstream analyses including in vitro expansion and gene sequencing

• Automated Operation for Enhanced Research Efficiency

• Automated cell sorting and target cell enrichment with one-touch sample loading

• Compatible with various sample types such as peripheral blood, pleural effusion, ascites, and cerebrospinal fluid, meeting high-throughput research demands

• Suitable for Both Clinical and Research Applications

• FDA and CE certified, meeting international quality standards

• Extensive clinical data on rare cell sorting and enrichment; validated with over 1,000 clinical samples, achieving >95% clinical sensitivity across multiple cancer types

Collaboration Outlook: Advancing the Precision Medicine Ecosystem in Asia-Pacific

This collaboration is not just about installing equipment; it represents a deep integration of technology, data, and talent. Labris will work closely with the NUS team to optimize sorting protocols and explore applications in precision medicine, cell culture, and early cancer screening. Labris's engineering team has already traveled to Singapore to provide systematic training and will offer long-term technical support.

We look forward to this partnership enabling Labris's "enabling technology" to make even greater contributions to precision medicine research in the Asia-Pacific region and beyond, truly putting technology at the service of human health.